TradingFloor AI · Stock Terminal

APGE - Ticker AI Digest

Apogee Therapeutics, Inc. Common Stock 📰 2
134.97000000 | Today 0.01% ●
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
Apogee Therapeutics, Inc. Common Stock in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
APGE Data 2026-08-31 Preview Mode
Core Deck
Deep Dive Modules
Home

Digested News

Today's Catalysts (APGE) 2
APGE 14:45
Apogee Therapeutics, Inc. Common Stock
Buy these quality, low-stress stocks for the summer, says Jefferies
APGE 08:50
Apogee Therapeutics, Inc. Common Stock
The Dividend ETF Quietly Outperforming the S&P 500
AI 2
APGE 15:11
Apogee Therapeutics, Inc. Common Stock
Stocks Supported by Strength in Chipmakers and AI-Infrastructure Stocks
APGE 13:11
Apogee Therapeutics, Inc. Common Stock
Stocks Supported by Strength in Chipmakers and AI-Infrastructure Stocks
Acquisitions 3
APGE 19:05
Apogee Therapeutics, Inc. Common Stock
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
APGE 19:05
Apogee Therapeutics, Inc. Common Stock
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
APGE 03:41
Apogee Therapeutics, Inc. Common Stock
Wells Fargo Maintains Overweight on AbbVie (ABBV), Sees Value in Apogee Acquisition
Admission 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 1
APGE 23:07
Apogee Therapeutics, Inc. Common Stock
AbbVie (ABBV) Wins Health Canada Approval for Boey
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
BlockListing 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Circular 0
No items for this category on selected date.
ClinicalTrial 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 10
APGE 02:35
Apogee Therapeutics, Inc. Common Stock
Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook
APGE 18:15
Apogee Therapeutics, Inc. Common Stock
AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
APGE 21:56
Apogee Therapeutics, Inc. Common Stock
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?
APGE 17:59
Apogee Therapeutics, Inc. Common Stock
AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree
APGE 14:12
Apogee Therapeutics, Inc. Common Stock
AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers
APGE 11:58
Apogee Therapeutics, Inc. Common Stock
AbbVie Strikes $10.9 Billion Deal for Apogee to Strengthen Future Immunology Portfolio (ABBV)
APGE 07:46
Apogee Therapeutics, Inc. Common Stock
Apogee soars on AbbVie deal report; analysts bullish
APGE 14:07
Apogee Therapeutics, Inc. Common Stock
AbbVie's biggest deal since 2019 could land soon
APGE 10:56
Apogee Therapeutics, Inc. Common Stock
AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics
APGE 07:04
Apogee Therapeutics, Inc. Common Stock
Stocks Slide as Focus Shifts to Iran Deal Hurdles: Markets Wrap
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
DirectorateChange 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Dividend 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Form83 0
No items for this category on selected date.
GeneralMeeting 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
IssueOfEquity 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 1
APGE 14:50
Apogee Therapeutics, Inc. Common Stock
Top Midday Stories: Treasury Authorizes Sale of Iranian Oil; SpaceX launches First Inaugural Bond Issuance
Litigation 0
No items for this category on selected date.
MonthlyFactsheet 0
No items for this category on selected date.
NAV 0
No items for this category on selected date.
NameChange 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 1
APGE 21:14
Apogee Therapeutics, Inc. Common Stock
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
OwnShares 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
ProfitWarning 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Prospectus 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
SchemeOfArrangement 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
TVR 0
No items for this category on selected date.
Takeover 2
APGE 10:55
Apogee Therapeutics, Inc. Common Stock
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
APGE 12:16
Apogee Therapeutics, Inc. Common Stock
AbbVie Goes On The Offensive With $10.9 Billion Takeover
US News 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 6
APGE 18:50
Apogee Therapeutics, Inc. Common Stock
Update: US Equity Indexes Mixed as Communication Services Sector Slides, Treasury Yields Surge
APGE 18:43
Apogee Therapeutics, Inc. Common Stock
Sector Update: Healthcare Stocks Rise Late Afternoon
APGE 17:11
Apogee Therapeutics, Inc. Common Stock
Update: Equities Mixed Intraday, Oil Falls as US-Iran Talks Advance
APGE 17:04
Apogee Therapeutics, Inc. Common Stock
Update: US Equity Indexes Mixed Amid Steep Decline in Communication Services, Surging Treasury Yields
APGE 16:47
Apogee Therapeutics, Inc. Common Stock
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
APGE 11:45
Apogee Therapeutics, Inc. Common Stock
Update: US Equity Futures Slightly Higher Pre-Bell As US-Iran Talks Start in Switzerland
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 1
APGE 17:05
Apogee Therapeutics, Inc. Common Stock
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
All Market News (Last 30 Days) 75
APGE 14:45
Apogee Therapeutics, Inc. Common Stock
Buy these quality, low-stress stocks for the summer, says Jefferies
APGE 08:50
Apogee Therapeutics, Inc. Common Stock
The Dividend ETF Quietly Outperforming the S&P 500
APGE 12:35
Apogee Therapeutics, Inc. Common Stock
Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?
APGE 12:35
Apogee Therapeutics, Inc. Common Stock
Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?
APGE 11:56
Apogee Therapeutics, Inc. Common Stock
J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
APGE 08:34
Apogee Therapeutics, Inc. Common Stock
Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders
APGE 20:31
Apogee Therapeutics, Inc. Common Stock
Q2 US Private Credit Wrap: Software under scrutiny as market recalibrates
APGE 19:05
Apogee Therapeutics, Inc. Common Stock
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
APGE 19:05
Apogee Therapeutics, Inc. Common Stock
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
APGE 15:34
Apogee Therapeutics, Inc. Common Stock
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
APGE 22:53
Apogee Therapeutics, Inc. Common Stock
XBI Ignored The Market's Downturn
APGE 13:19
Apogee Therapeutics, Inc. Common Stock
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?
APGE 13:01
Apogee Therapeutics, Inc. Common Stock
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
APGE 12:05
Apogee Therapeutics, Inc. Common Stock
Notable healthcare headlines for the week: Merck, AbbVie, and Bayer in focus
APGE 23:07
Apogee Therapeutics, Inc. Common Stock
AbbVie (ABBV) Wins Health Canada Approval for Boey
APGE 18:21
Apogee Therapeutics, Inc. Common Stock
AbbVie (ABBV) to Acquire Apogee Therapeutics
APGE 17:05
Apogee Therapeutics, Inc. Common Stock
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
APGE 20:15
Apogee Therapeutics, Inc. Common Stock
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
APGE 20:15
Apogee Therapeutics, Inc. Common Stock
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
APGE 13:13
Apogee Therapeutics, Inc. Common Stock
Is AbbVie a Buy After Its Purchase of Apogee?
APGE 02:35
Apogee Therapeutics, Inc. Common Stock
Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook
APGE 13:39
Apogee Therapeutics, Inc. Common Stock
Spyre falls after $2M insider sale
APGE 09:15
Apogee Therapeutics, Inc. Common Stock
AbbVie (ABBV) Stock Draws Fresh Price Target Split After Apogee Deal
APGE 00:20
Apogee Therapeutics, Inc. Common Stock
Halper Sadeh LLC is Investigating Whether APGE, LPRO, HUN, AVNS are Obtaining Fair Deals for their Shareholders
APGE 18:15
Apogee Therapeutics, Inc. Common Stock
AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
APGE 13:50
Apogee Therapeutics, Inc. Common Stock
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout
APGE 12:25
Apogee Therapeutics, Inc. Common Stock
Company News for Jun 23, 2026
APGE 10:55
Apogee Therapeutics, Inc. Common Stock
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
APGE 03:41
Apogee Therapeutics, Inc. Common Stock
Wells Fargo Maintains Overweight on AbbVie (ABBV), Sees Value in Apogee Acquisition
APGE 02:18
Apogee Therapeutics, Inc. Common Stock
Why AbbVie Stock Jumped Today
APGE 00:53
Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics (APGE) Hits Fresh High on AbbVie $10.9B Merger
APGE 21:56
Apogee Therapeutics, Inc. Common Stock
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?
APGE 21:46
Apogee Therapeutics, Inc. Common Stock
Stocks Mostly Lower on Weakness in Megacap Tech and Software Stocks
APGE 21:14
Apogee Therapeutics, Inc. Common Stock
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
APGE 19:53
Apogee Therapeutics, Inc. Common Stock
The $11 Billion Reason Abbvie Stock Is Up Today
APGE 19:36
Apogee Therapeutics, Inc. Common Stock
Stocks Mostly Lower on Weakness in Megacap Tech and Software Stocks
APGE 18:50
Apogee Therapeutics, Inc. Common Stock
Update: US Equity Indexes Mixed as Communication Services Sector Slides, Treasury Yields Surge
APGE 18:47
Apogee Therapeutics, Inc. Common Stock
Abbvie acquiring Apogee for $10.9B, Coca-Cola vs. IRS in appeals court
APGE 18:43
Apogee Therapeutics, Inc. Common Stock
Sector Update: Healthcare Stocks Rise Late Afternoon
APGE 17:59
Apogee Therapeutics, Inc. Common Stock
AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree
APGE 17:11
Apogee Therapeutics, Inc. Common Stock
Update: Equities Mixed Intraday, Oil Falls as US-Iran Talks Advance
APGE 17:07
Apogee Therapeutics, Inc. Common Stock
Top Midday Gainers
APGE 17:04
Apogee Therapeutics, Inc. Common Stock
Update: US Equity Indexes Mixed Amid Steep Decline in Communication Services, Surging Treasury Yields
APGE 16:47
Apogee Therapeutics, Inc. Common Stock
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
APGE 15:56
Apogee Therapeutics, Inc. Common Stock
Stocks Erase Early Gains as Alphabet and Software Companies Fall
APGE 15:13
Apogee Therapeutics, Inc. Common Stock
AbbVie (ABBV) Is Buying Apogee Therapeutics For $10.9 Billion
APGE 15:11
Apogee Therapeutics, Inc. Common Stock
Stocks Supported by Strength in Chipmakers and AI-Infrastructure Stocks
APGE 14:50
Apogee Therapeutics, Inc. Common Stock
Top Midday Stories: Treasury Authorizes Sale of Iranian Oil; SpaceX launches First Inaugural Bond Issuance
APGE 14:23
Apogee Therapeutics, Inc. Common Stock
Stocks Erase Early Gains as Alphabet and Software Companies Fall
APGE 14:12
Apogee Therapeutics, Inc. Common Stock
AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers
APGE 13:23
Apogee Therapeutics, Inc. Common Stock
Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics
APGE 13:15
Apogee Therapeutics, Inc. Common Stock
Market Minute 6-22-26- Mideast Talks in Flux; Prime Day Looms
APGE 13:11
Apogee Therapeutics, Inc. Common Stock
Stocks Supported by Strength in Chipmakers and AI-Infrastructure Stocks
APGE 13:04
Apogee Therapeutics, Inc. Common Stock
AbbVie to acquire Apogee Therapeutics in $10.9B deal
APGE 12:38
Apogee Therapeutics, Inc. Common Stock
AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal
APGE 12:16
Apogee Therapeutics, Inc. Common Stock
AbbVie Goes On The Offensive With $10.9 Billion Takeover
APGE 12:09
Apogee Therapeutics, Inc. Common Stock
Pre-Market Movers: TNON, ADTX, LNAI See Sharp Moves
APGE 12:08
Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, BitFuFu rise premarket; AbbVie gains after deal
APGE 11:58
Apogee Therapeutics, Inc. Common Stock
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Amid Continued US-Iran Talks
APGE 11:58
Apogee Therapeutics, Inc. Common Stock
AbbVie Strikes $10.9 Billion Deal for Apogee to Strengthen Future Immunology Portfolio (ABBV)
APGE 11:45
Apogee Therapeutics, Inc. Common Stock
Update: US Equity Futures Slightly Higher Pre-Bell As US-Iran Talks Start in Switzerland
APGE 11:44
Apogee Therapeutics, Inc. Common Stock
Markets News, June 22, 2026: Dow Ekes Out Gain as Big Tech Stocks Weigh on Nasdaq; SpaceX Falls To Lowest Close Ever
APGE 11:32
Apogee Therapeutics, Inc. Common Stock
AbbVie acquires Apogee Therapeutics for $10.9 billion
APGE 11:23
Apogee Therapeutics, Inc. Common Stock
AbbVie’s $10.9 Billion Apogee Therapeutics Buyout Protects Its Immunology Crown
APGE 11:08
Apogee Therapeutics, Inc. Common Stock
5 Things to Know Before the Stock Market Opens
APGE 10:36
Apogee Therapeutics, Inc. Common Stock
Stocks making the biggest moves premarket: Apogee Therapeutics, SpaceX, Arcosa & more
APGE 10:00
Apogee Therapeutics, Inc. Common Stock
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
APGE 09:54
Apogee Therapeutics, Inc. Common Stock
A major test is coming for the stock market, and Morgan Stanley warns that the Fed won’t rescue investors
APGE 09:37
Apogee Therapeutics, Inc. Common Stock
Stocks Set to Open Mixed as Investors Weigh U.S.-Iran Progress, PCE Inflation Data and Fed Speak Awaited
APGE 08:56
Apogee Therapeutics, Inc. Common Stock
Intel, Micron, SpaceX, Apogee Therapeutics, and More Stocks That Explain Today’s Market
APGE 08:32
Apogee Therapeutics, Inc. Common Stock
Biggest stock movers Monday: APGE, GETY, and more
APGE 07:46
Apogee Therapeutics, Inc. Common Stock
Apogee soars on AbbVie deal report; analysts bullish
APGE 14:07
Apogee Therapeutics, Inc. Common Stock
AbbVie's biggest deal since 2019 could land soon
APGE 10:56
Apogee Therapeutics, Inc. Common Stock
AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics
APGE 07:04
Apogee Therapeutics, Inc. Common Stock
Stocks Slide as Focus Shifts to Iran Deal Hurdles: Markets Wrap

Today's AI

APGE · Agentic Market Intelligence

APGE intelligence is listening.

The engine is monitoring news, price structure, forecasts and financial changes. New scored evidence will appear here against this stock automatically.

Live catalyst scoringAI price pathsRisk-aware triggersFinancial blend
AI bias0.0
Bullish0
Bearish0
Today's AI Starts With News

2 live catalysts is opening Today’s AI for APGE.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2026-08-31 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
2 Today
Front Of Desk
Apogee Therapeutics, Inc. Common Stock has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
14:45 Today's Catalyst Buy these quality, low-stress stocks for the summer, says Jefferies 08:50 Today's Catalyst The Dividend ETF Quietly Outperforming the S&P 500
Single-Ticker Today's AI
APGE signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for Apogee Therapeutics, Inc. Common Stock. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full APGE Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for APGE on 2026-08-31.

Fundamentals Matrix

About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

🌐 Visit Official Website ↗

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
10.1B
Enterprise Value
9.0B
Public Float
94.0
Broker Target
130.5275
Shares Out
61.7M
Long Interest
0
Short Interest
0
Exchange
NASDAQ
Currency Code
USD
ISIN
US03770N1019
Ex-Dividend
-
Yield
0.00%
Dividend Rate
-
EPS
-4.34
Market
NASDAQ
Standard Lists
Not currently ranked
Sector
Software and Computer ServicesUS fundamentals
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

2 live alerts now opens the financials desk for APGE.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2026-08-31 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
2 Alerts
Front Of Desk
Apogee Therapeutics, Inc. Common Stock has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
14:45 Today's Alert Buy these quality, low-stress stocks for the summer, says Jefferies 08:50 Today's Alert The Dividend ETF Quietly Outperforming the S&P 500
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
-
Earnings Date
-
Net Debt
-122.7M
Cash
131.5M
EPS
-4.34
Net Income
-255.8M
Revenue
0
Enterprise Value
9.0B
Trailing PE
-
Forward PE
-
Price Sales TTM
-
Price Book MRQ
8.0013
EV Revenue
-
EV EBITDA
-
Financial Forecastist

Mixed financial engine

Net debt is building +366.6%.

Net Income +33.9% FCF +5.3% Current Ratio 32.59x Forward Rev 0
Mixed
Quarter Revenue
0
-
vs prior comparable quarter
Net Margin
-
-
profitability pulse
Free Cash Flow
-55.6M
+5.3%
cash conversion
Net Debt / EBITDA
6.0x
+366.6%
lower is cleaner
Revenue Engine

Latest quarter printed 0 with the top line stable against the last comparable period.

Profit Stack

Net income landed at -74.1M and the margin profile is stable. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 451.8M while net debt is -443.8M. The leverage stack is moving the wrong way.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q3 2025
Consensus
0
Revenue Path
-1.15
EPS / Earnings
Growth cue -0.3%
Q1 2026
Consensus
0
Revenue Path
-1.13
EPS / Earnings
Growth cue -0.2%
Q2 2026
Consensus
10.0M
Revenue Path
-0.96
EPS / Earnings
Growth cue +0.1%
Q3 2026
Consensus
0
Revenue Path
-1.16
EPS / Earnings
Growth cue -0.0%
FY 2026
Consensus
9.1M
Revenue Path
-4.41
EPS / Earnings
Growth cue -0.0%
FY 2027
Consensus
12.5M
Revenue Path
-5.19
EPS / Earnings
Growth cue -0.2%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q1 2026 0 -74.1M -55.6M -443.8M
Q4 2025 0 -69.4M -62.8M -122.7M
Q3 2025 0 -65.0M -54.3M -98.1M
Q2 2025 0 -66.1M -62.8M -113.3M
Q1 2025 0 -55.3M -52.8M -95.1M
Q4 2024 130.0K -67.2M -67.7M -130.0M

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 0 -255.8M -254.1M -232.6M
FY 2024 0 -182.1M -181.9M -172.3M
FY 2023 0 -84.0M -75.0M -74.9M
FY 2022 0 -39.8M -39.8M -16.4M

Structure DNA

Market Structure DNA

Institutional Trend Leader profile with trend runway open

Price is 129.0% through the 52-week range, +67.7% vs 50DMA and +114.4% vs 200DMA. 100.0% of the register is locked by institutions and insiders, leaving 0.0% free float. Capital rhythm reads no cadence with forward yield near 0.0% and payout around 0.0%.

Trend runway open Institutional gravity Moderate income rhythm As Of 2026-07-14
Institutional Trend Leader
Structure Score
72.5 / 100
Institutional Trend Leader
Trend Stack
+67.7% / +114.4%
vs 50DMA / 200DMA
52W Position
129.0%
auction position inside the yearly range
Ownership Lock
100.0%
110.3% institutions | 5.8% insiders
Pressure Pocket
10.8% short float
Short ratio 0.9x | monthly -50.7%
Capital Rhythm
No cadence
Yield 0.0% | payout 0.0%
Trend Runway

Implied spot is 163.07 with the stock +67.7% vs 50DMA and +114.4% vs 200DMA. The tape is sitting 129.0% through the 52-week range, which frames the regime as trend runway open.

Ownership Register

Institutions hold about 110.3% and insiders about 5.8%, locking roughly 100.0% of the register and leaving 0.0% in free float. That reads as institutional gravity.

Pressure Pocket

Short pressure is running near 10.8% of float with short ratio 0.9x and monthly change -50.7%. That gives us a read on whether the tape is clean, crowded, or coiled.

Capital Rhythm

Dividend cadence reads no cadence with - event(s) in the last full year, a five-year average of -, and stability score 0.0/100. Forward yield sits near 0.0% while payout is around 0.0%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

No cadence
Year Dividend Count Context
Dividend history has not been normalized yet.

Structure Facts

Live Snapshot
Implied Spot
163.07
derived from market cap / shares
52W High
134.13
upper auction edge
52W Low
34.34
lower auction edge
Beta
0.33
volatility character
Shares Out
61.7M
fully diluted count
Shares Float
58.0M
tradable register
Shares Short
5.2M
borrowed stock
Short Ratio
0.9x
days-to-cover style read
Ex-Dividend
-
next ex-date not supplied
Dividend Pay
-
payment date not supplied
Last Split
-
split date not supplied

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
114.5343
Institutions As Of
2026-05-31
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
0
Sale TR1
0
Broker Coverage Rows
0
Institution Holders Tracked
40
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data · APGE · Last 30 Days

Short D · 12/26 EMA spread with 9 signal

Red histogram bars show short loading accelerating. Green bars show short covering accelerating. The two lines expose the crossover before the raw holder table does.

Short D waiting

Building APGE short-momentum read

Short D compares the ticker’s disclosed short-position momentum with its own signal line.

Short D—
Signal—
Momentum—

Declared Short Holders

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for APGE, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2026-08-31 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
2 Today
Catalyst Pulse
Apogee Therapeutics, Inc. Common Stock has fresh news flow live now, so the tape is framing the chart workspace below.
14:45 Today's Catalyst Buy these quality, low-stress stocks for the summer, says Jefferies 08:50 Today's Catalyst The Dividend ETF Quietly Outperforming the S&P 500
AI Charts Studio
APGE Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-08-31 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
AI AutoDetection Automatic bull / bear chart read
Detected market structure
Analysing selected range
Why this call
Waiting for sufficient price history.
Invalidation
—
Updates with the timeframe.
Bull caseCalculating upside confirmation.
Bear caseCalculating downside confirmation.
Indicators0
Technicals0
RSI Gauge
Price Change
AI Forecast